Integrated Filing (Financial) for the quarter and nine-months endedon 31st December, 2025
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indo Us Biotech Limited has submitted its Integrated Filing (Financial) to NSE for the quarter and nine months ended 31st December, 2025. This is a standard SEBI-mandated combined submission that bundles the unaudited financial results, limited review report from the statutory auditor, shareholding pattern, and other corporate governance disclosures into a single document. Specific revenue, profit, expense, and balance sheet figures would be available in the detailed filing attached to the announcement. The integrated format was introduced to reduce the volume of separate filings that listed companies make each quarter.
This is a routine regulatory compliance filing and is unlikely to have a direct short-term impact on the stock price. Investors should review the attached financial results and auditor's report for any material changes in business performance, segment trends, or governance matters before making decisions.